partner news-小9直播体育免费直播下载ios

bioray, tot biopharms cdmo partner, announced that its application for clinical trials of bry812 injection, a class 1 innovative biological product independently developed by itself, has been accepted by nmpa. bry812 is a novel antibody-drug conjugate (ad

recently, tot biopharm’s cdmo partner, medilink therapeutics, announced that its self-developed innovative antibody - drug conjugates (adc) yl202 has received default approval from the fda to conduct clinical trials for the treatment of advanced solid tum

tot biopharm (stock code: 1875.hk) announced that the cdmo service for commercial scale-up and manufacture of covid-19 specific neutralizing antibody injection (jmb2002) for its partner jemincare has completed in mid-august, one and a half months ahead of

on july 19, tot biopharm (1875.hk) and brightgene (688166.sh) jointly announced that the two companies will develop a strategic collaboration for antibody-drug conjugates (adc) cdmo services to facilitate the development and commercialization of innovativ